BioSpecifics Technologies Corp.

Who: Endo International/BioSpecifics Technologies What: The companies agree to a deal in which BioSpecifics will become a subsidiary of Endo, giving the latter all rights to injected collagenase dr

Takeda Pharmaceutical Co. Ltd. has reported the first Phase III data for the investigational uterine fibroid treatment relugolix in Japanese patients in a study that is seen as a bellwether for larg

Lynbrook, New York-based BioSpecifics Technologies, a biopharmaceutical company developing first-in-class collagenase-based products, has named two new members to its board of directors: Jennifer Chao

Auxilium Pharmaceuticals Inc. will focus its initial marketing efforts of Xiaflex (collagenase clostridium histolyticum) for Peyronie’s disease patients to the small population of urologists who c